Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach-Reference-Cited by-同舟云学术

Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach

Published:2021-06 Issue: Volume:138 Page:111544
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Molavi Zahra,Razi Sara,Mirmotalebisohi Seyed Amir,Adibi Amirjafar,Sameni Marzieh,Karami Farshid,Niazi Vahid,Niknam Zahra,Aliashrafi Morteza,Taheri Mohammad,Ghafouri-Fard Soudeh,Jeibouei Shabnam,Mahdian Soodeh,Zali Hakimeh,Ranjbar Mohammad Mehdi,Yazdani Mohsen

Funder

Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference119 articles.

1. Drug treatment options for the 2019-new coronavirus (2019-nCoV);Lu;Biosci. Trends,2020

2. SARS-CoV-2 and COVID-19: between pathophysiology complexity and therapeutic uncertainty;Romagnoli;Physiol. Rev.,2020

3. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor;Kim;PLoS Pathog.,2016

4. Common and unique features of viral RNA-dependent polymerases;te Velthuis;Cell. Mol. Life Sci.,2014

5. Coronavirus Main Proteinase: Target for Antiviral Drug Therapy, Coronaviruses with Special Emphasis on First Insights Concerning SARS;Anand,2005

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the puzzle: non-defining mutations in SARS-CoV-2 proteome may affect vaccine effectiveness;Frontiers in Public Health;2024-08-15

2. Boosting immunity: synergistic antiviral effects of luteolin, vitamin C, magnesium and zinc against SARS-CoV-2 3CLpro;Bioscience Reports;2024-08

3. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2;Antiviral Research;2024-07

4. Arylamines QSAR-Based Design and Molecular Dynamics of New Phenylthiophene and Benzimidazole Derivatives with Affinity for the C111, Y268, and H73 Sites of SARS-CoV-2 PLpro Enzyme;Pharmaceuticals;2024-05-09

5. Repurposing of Rutan showed effective treatment for COVID-19 disease;Frontiers in Medicine;2023-11-29